Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-28

Clinical Trial Update: To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets [Phase 1]

View source ↗

Summary

Phase 1 study reporting the relative bioavailability of hydroxychloroquine sulfate 200 mg tablets; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Hydroxychloroquine sulfate 200 mg tablets (hydroxychloroquine sulfate)

Snippet

Sponsor: Sandoz | Conditions: Immunosuppression, Rheumatism | Phase 1 | Status: COMPLETED